Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019

MARKET OUTLOOK

Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage treatment. Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the conventional standard of care for R/RDLBCL followed by conditioning and autologous or allogeneic stem cell transplantation (SCT) in eligible patients. The anti-CD19 CAR T-cell therapies Yescarta (Gilead/Kite) and Kymriah (Novartis) have expanded treatment options for patients with DLBCL, although their current use is restricted to third and subsequent lines of therapy. Despite the evolving market landscape, significant unmet need remains in the treatment of R/RDLBCL due to the limited availability of effective treatment options.

QUESTIONS ANSWERED

What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
How do current therapies perform on key clinical attributes for R/R DLBCL?
What are the major unmet needs and the most lucrative opportunities in R/R DLBCL?
When considering new treatment options in this setting, what trade-offs are acceptable to surveyed hematologist-oncologists between key clinical attributes and cost of therapy?

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 U.S. hematologist-oncologists and 30 European hematologist-oncologists.

Key companies: Gilead, Kite Pharma, Novartis, Roche / Genentech.

Key drugs: Rituximab, Yescarta, Kymriah.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Contact sales account_box

Report

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…

north_east

Report

Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)

China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…

north_east

Report

Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)

The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…

north_east

Report

Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…

north_east

Report

Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)

Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…

north_east

Product logins

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019

Related Market Assessment Reports

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)

Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)

Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)

Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)

Follow us

Contact us